Investors

Amplyx is a privately held company advancing the clinical development of fosmanogepix and MAU868 for treatment of life-threatening diseases. Our largest investors are:

Latest News

Milestones Along Our Journey

Subscribe to News Updates

August 5, 2020/by ksmith

Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences

July 22, 2020/by ksmith

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

June 24, 2020/by ksmith

Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020

June 8, 2020/by eallison

Amplyx Pharmaceuticals Expands Executive Leadership Team

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

April 29, 2020/by ksmith

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

September 24, 2019/by eallison

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

September 16, 2019/by eallison

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

Press Release Archive

Corporate Presentation

If you’re a member of the media
and would like to reach Amplyx, please contact:

Heidi Chokeir, Ph.D.
Canale Communications
(619) 849-5377 | heidi@canalecomm.com